CrossAssetDataThe Company File
···
ARDX

Ardelyx, Inc.

Ardelyx, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Fremont, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $407 million and a loss of $62 million (its filed statements).

Product business Pharmaceutical Preparations Fremont, CA filings since 2008 8 of 9 filed, 1 estimated
Ask the desk about ARDX → Compare ARDX with PHAR → Price chart on TradingView ↗ Full EDGAR file ↗ Watch ARDX →

Sector peers: PHARRIGLVNDATBPH

5.8/10headline grade
vs its business-model standard
5.0/10past 6.6/10present 5.7/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.8 out of ten, 8 of 9 metrics filed and 1 estimated: past 5.0 out of ten, present 6.6 out of ten, future 5.7 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 5.0 out of ten. 1 warning event since 2017; the latest 2022-05-27. 50th percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 5.2 out of ten. +32.8% a year over 9 filed years; profitable in 0 of 9. 52nd percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 4.5 out of ten. CrossAssetData estimate 4.5/10, confidence 35 of 100 (one part). 45th percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Financial health (present): 6.3 out of ten. ROE -37%: lost 37¢ per shareholder dollar. Leverage 67%: owes 67¢ per asset dollar. 63rd percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 7.8 out of ten. top 22% of 314 in its family; net margin -15.1%. 78th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 5.3 out of ten. top 47% of 315 in its family for leadership; chief executive since 2014. 53rd percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 4.5 out of ten. bottom 45% of 272 in its family for room to expand. 45th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 8.4 out of ten. top 16% of 307 in its family for growth drivers. 84th percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 3.9 out of ten. bottom 39% of 234 in its family for expectations against reality. 39th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-02-19 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 4, 2026-08-25. Filings on record since 2008. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Product IBSRELA 67%, Product XPHOZAH 25%, Product Supply Revenue 4%, Non Cash Royalty Related to Sale of Future Royalties 2%, License 1%. By geography: United States 93%, Asia Pacific 7%, North America under 1%. As tagged in its annual report (Form 10-K, filed 2026-02-19).

Who runs it

Raab, Michael (President & CEO); Reilly, Joseph James (Senior Vice President and Chief Accounting Officer); Hohenleitner, Susan (Chief Financial Officer); Renz, Justin A (Chief Financial Officer); Bishop, John E (Chief Technical and Quality Officer); Brady, James Parker (Chief Human Resources Officer); Foster, Eric Duane (Chief Commercial Officer); Kelliher, Mike (Chief Business Officer); Williams, Laura A (Chief Patient Officer); Ettenberg, Felecia (Chief Legal Officer); and 10 more. 20 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.